DRMA — Dermata Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1853816 ·
Last close
$0.57
Market Cap
$2.81M
52W High
$4.66
52W Low
$0.57
ADV30
5,885,688
Next earnings
—
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 74,137 40,129 -2,858,499 -2,821,400 6,635,491 4,822,357 2,729,565
Jun 2026 0 — -3,013,567 -2,967,063 5,320,799 4,412,764 1,833,079
Mar 2026 0 — -1,926,382 -1,847,706 7,465,652 6,945,282 1,052,649
Dec 2025 0 — -1,900,393 -1,861,888 7,863,826 7,521,978 1,640,446

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-8,034,258
Investing CF
—
Financing CF
$6,076,759
CapEx
—
Dividends Paid
—
Buybacks
$-367
EPS Diluted TTM
$-4.53
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-78,048,665
Inventory
$149,734
Receivables
—
ST Investments
—
EBIT TTM
$-8,601,013
Pretax Income TTM
$-8,368,646
Interest Exp TTM
—
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$74,137
EBITDA
—
Free Cash Flow
$-5,651,833
Enterprise Value
$-1,759,712
Total Cash
$4,822,357
Total Debt
$0
Shares Out
4,930,207
Trailing EPS
$-4.39
Book Value
$0.79
ROE
-241.5%
ROA
-103.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -7,773,598 -7,558,557 7,863,826 1,640,446 6,223,380 -7,757,559
Dec 2024 0 -12,513,242 -12,287,461 3,533,888 1,972,794 1,561,094 -11,162,948
Dec 2023 0 -8,041,906 -7,794,690 7,978,634 1,623,616 6,355,018 -6,408,931
Dec 2022 0 -9,674,486 -9,610,913 6,944,488 922,634 6,021,854 -8,834,164

TTM Snapshot

Revenues TTM
$232,367
NetIncome TTM
$-8,368,646
OpCashFlow TTM
—
Assets (Latest)
$5,320,799
Forward EPS
$-3.87

Peers — same industry

TickerNameMarket CapLastDaily %
PPBT PURPLE BIOTECH LTD. $2.78M $1.71 —
NRSN NeuroSense Therapeutics Ltd. $2.86M $1.51 —
GELS Gelteq Ltd $2.88M $0.27 —
MDCX Medicus Pharma Ltd. $2.89M $1.52 —
APUS Apimeds Pharmaceuticals US, Inc. $2.94M $1.95 —

News headlines (Yahoo Finance, 1h cache)

Dermata Announces U.S. Trademark Registration for TOME(R)
2026-11-18 13:35 · Yahoo
Dermata Highlights Additional Results and Photos from Cosmetic Study Evaluating Its Tome Foundational Treatment
2026-11-17 13:30 · Yahoo
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Third Quarter 2026
2026-11-10 21:05 · Yahoo
Dermata Therapeutics Highlights Media Recognition of Tome Skincare Following Commercial Launch
2026-11-05 13:30 · Yahoo
Dermata Advances Second Tome Skincare Product Toward Expected 2027 Launch with Initiation of Acne Clinical Trial
2026-10-29 20:05 · Yahoo
Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
2026-10-15 12:05 · Yahoo
Papulopustular Rosacea Market Report Now Available, Covers 11 Countries Across North America, Europe, and Asia-Pacific, Profiling Galderma, Journey Medical, Dermata Therapeutics, and Dr. Reddy's Labor
2026-08-31 09:05 · Yahoo
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
2026-08-25 12:30 · Yahoo
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
2026-08-21 12:30 · Yahoo
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
2026-08-11 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.